XLXiangzhao Li

Xiangzhao Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiangzhao Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 30 November 2020
      • Vol. 40  (11) , 1645-1650

    微卫星不稳定性类型及临床病理特征:基于1394例结直肠癌患者的标本检测

    by Xiangzhao Li, Huanjiao Liu, Minyi Liang, Huihui Chen, Li Liang

    研究微卫星不稳定性(MSI)结直肠癌病人错配修复(MMR)基因突变的类型和临床病理特征。 收集南方医科大学南方医院2016~2018年1394例结直肠癌病人石蜡标本,采用免疫组化染色技术检测MMR蛋白; MSI基因检测106例dMMR病例,46例肿瘤细胞呈异质性表达的pMMR病例和147例随机选择的pMMR病例; 分析错配修复蛋白缺失与结直肠癌临床病理特征参数的关系; 比较两种方法检测结果的一致性。 MMR蛋白缺失发生率占总结直肠癌病人的7.6%,缺失类型主要为MLH1、PMS2双缺失,占总缺失的55.7%;MMR蛋白缺失与结直肠癌患者的年龄、发生部位、大体分型、肿瘤大小、组织学分型、分化程度和临床TNM分期均有关(P < 0.05),而与患者的性别无关(P=0.47);dMMR结直肠癌病人具有典型的临床病理特征:MMR蛋白缺失在年龄 < 50岁、右半结肠、肿瘤直径 > 6 cm、腺癌伴粘液腺癌或粘液分泌的混合型癌、低分化腺癌和TNM分期Ⅰ/Ⅱ期组的发生率高; 免疫组化和PCR-毛细管电泳法在结直肠癌微卫星不稳定性检测结果一致性为98.7%。 微卫星不稳定性错配修复蛋白表达缺失(dMMR)在结直肠癌的主要类型为MLH1、PMS2双缺失,具有典型的临床病理特征,其发生率低于西方报道; 免疫组化和PCR毛细管电泳法的检测结果显示高度的一致性。


  • An evidence-based etiology study of synovial cyst of knee cruciate ligament: a real or pseudo-cyst

    by Jun Xiao, Yong Hu, Kai-Ying Tang, Tahsin Tarik Torsha, Yu Xu, Zhi-Han Li, Xiang-Zhao Li, Zhan-Jun Shi

    Synovial cyst of knee cruciate ligament (SCKCL) is a rare condition but can cause severe knee pain. The understanding of its etiology is relatively poor. This current study aimed to elucidate the pathogenesis of SCKCL based on a series of histo- and cytopathological examination.


  • Open Access

    The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

    by Xiaolei Wei, Meng Xu, Yongqiang Wei, Fen Huang, Tong Zhao, Xiangzhao Li, Ru Feng, B Hilda Ye

    Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.